

Andras A Heczey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4437333/publications.pdf>

Version: 2024-02-01

43
papers

1,924
citations

471509

17
h-index

345221

36
g-index

45
all docs

45
docs citations

45
times ranked

2993
citing authors

#	ARTICLE	IF	CITATIONS
1	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. <i>Molecular Therapy</i> , 2017, 25, 2214-2224.	8.2	378
2	Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. <i>Blood</i> , 2014, 124, 2824-2833.	1.4	229
3	Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. <i>Hepatology</i> , 2017, 65, 104-121.	7.3	192
4	Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. <i>Nature Medicine</i> , 2020, 26, 1686-1690.	30.7	159
5	Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2020, 8, 309-320.	3.4	134
6	CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. <i>Journal of Clinical Investigation</i> , 2016, 126, 2341-2355.	8.2	127
7	IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. <i>Journal of Clinical Investigation</i> , 2012, 122, 2221-2233.	8.2	126
8	NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced <i>In Vivo</i> Persistence and Antitumor Activity against Neuroblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 7126-7138.	7.0	112
9	Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. <i>Human Gene Therapy</i> , 2017, 28, 437-448.	2.7	72
10	Undifferentiated Embryonal Sarcoma of the Liver (UESL): A Single-Center Experience and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 261-268.	0.6	54
11	Health disparities are important determinants of outcome for children with solid tumor malignancies. <i>Journal of Pediatric Surgery</i> , 2015, 50, 161-166.	1.6	41
12	Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27745.	1.5	37
13	Vascular invasion is a prognostic indicator in hepatoblastoma. <i>Journal of Pediatric Surgery</i> , 2017, 52, 956-961.	1.6	29
14	Advances in chimeric antigen receptor immunotherapy for neuroblastoma. <i>Discovery Medicine</i> , 2013, 16, 287-94.	0.5	28
15	T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. <i>Molecular Therapy - Oncolytics</i> , 2017, 6, 69-79.	4.4	26
16	Targeting <i>O</i> -Acetyl-GD2 Ganglioside for Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2017, 2017, 1-16.	2.2	25
17	Cholangiocarcinoma Among Children and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, e12-e18.	1.8	21
18	Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. <i>Journal of Hepatology</i> , 2022, 77, 1026-1037.	3.7	21

#	ARTICLE	IF	CITATIONS
19	Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience. <i>Journal of Pediatric Surgery</i> , 2018, 53, 163-168.	1.6	17
20	Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29763.	1.5	15
21	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. <i>Blood</i> , 2022, 140, 16-24.	1.4	14
22	Liver transplant in a recently COVID-19 positive child with hepatoblastoma. <i>Pediatric Transplantation</i> , 2021, 25, e13880.	1.0	11
23	Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 695-699.	1.8	10
24	Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e415-e420.	0.6	6
25	Pediatric Oncology Patients With Vincristine-Induced Recurrent Laryngeal Nerve Palsy: Two Case Reports and a Brief Review of Literature. <i>Ear, Nose and Throat Journal</i> , 2021, 100, NP459-NP463.	0.8	6
26	A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2647-TPS2647.	1.6	6
27	Fatal Central Nervous System Post-transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, e21-e23.	1.8	4
28	Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e1181-e1185.	0.6	4
29	Liver abscesses secondary to Escherichia coli infection mimicking multifocal hepatoblastoma: A case report. <i>Journal of Pediatric Surgery Case Reports</i> , 2017, 18, 42-44.	0.2	3
30	Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28417.	1.5	3
31	Integration of a dedicated management protocol in the care of pediatric liver cancer: From specialized providers to complication reduction. <i>Journal of Pediatric Surgery</i> , 2022, 57, 1544-1553.	1.6	3
32	Osteopetrosis and Erlenmeyer-Flask Deformity. <i>New England Journal of Medicine</i> , 2015, 373, e12-e12.	27.0	2
33	Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1:6)(q25;p23) After Treatment for High-risk Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e486-e488.	0.6	2
34	Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells. <i>Molecular Therapy</i> , 2019, 27, 1348-1349.	8.2	2
35	50 Years Ago in T J P. <i>Journal of Pediatrics</i> , 2018, 203, 233.	1.8	1
36	Agenesis of the corpus callosum and hepatoblastoma. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 224-228.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, e14521-e14521.	1.6	1
38	396. Development of GD2-Specific Immunoliposomes for Immunotherapy of Neuroblastoma. Molecular Therapy, 2016, 24, S157.	8.2	0
39	645. T-Cell Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Molecular Therapy, 2016, 24, S255-S256.	8.2	0
40	Abstract 2997: Novel orthotopic patient-derived xenograft mouse models of hepatoblastoma that replicate tumor heterogeneity, chemoresistance, and refractory disease. , 2021, , .		0
41	The incidence of acute kidney injury among children treated for fever and neutropenia after elimination of empiric gentamycin use.. Journal of Clinical Oncology, 2012, 30, 120-120.	1.6	0
42	Outpatient management of pediatric oncology patients with low-risk fever and neutropenia: Implementation of new clinical practice guideline at Texas Children's Hospital.. Journal of Clinical Oncology, 2017, 35, 26-26.	1.6	0
43	Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors. Transplantation and Cellular Therapy, 2022, 28, S200-S201.	1.2	0